NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals (Nasdaq:NRXP) said Osmind presented a retrospective EHR study at the 2026 American Society of Clinical Psychopharmacology comparing IV racemic ketamine with intranasal esketamine in treatment-resistant depression. The analysis included 8,224 IV ketamine and 1,830 intranasal esketamine patients (matched to 3,560). Remission was 34% vs 26% and response 63% vs 58% (IV OR 1.22; P value not shown). The study was not randomized, limiting causal conclusions.
How this was made
The 30-second read
Why it matters
The poster provides comparative RWE favoring IV ketamine over intranasal esketamine on remission/response rates, supporting NRx’s strategic messaging for NRX-100, but does not constitute a new randomized efficacy result or regulatory milestone.
Market read
Directly relevant to NRx’s ketamine thesis via a conference poster, but the evidence is retrospective and non-randomized, limiting immediate trading impact.
What to watch
The dataset is limited to patients using Osmind’s EMR system, which may not represent all real-world ketamine/esketamine users nationwide.
Background
NRx is developing preservative-free IV ketamine (NRX-100) and positions its NMDA platform for CNS disorders; the company references FDA Type C discussions and the use of real-world evidence in depression approvals.
Ticker impact
NRx Pharmaceuticals highlights a peer-reviewed real-world evidence poster suggesting IV racemic ketamine shows higher remission/response than intranasal esketamine.
Modest positive bias; likely limited near-term price impact without new FDA decision or trial readout.
The article is a conference poster and RWE comparison (not a randomized trial) but is directly tied to NRx’s ketamine development and FDA engagement (Type C meeting).
Market effects
Reinforces broader real-world evidence acceptance for depression/suicidality therapeutics and could lift sentiment toward ketamine/esketamine competitors.
Primarily US-focused regulatory/clinical narrative; limited direct regional read-through.
US RWE emphasis may influence global development and evidence strategies for CNS depression therapies.
Counterpoint
Because treatment assignment was not randomized, differences in remission/response could reflect patient selection or clinic practices rather than true efficacy.
Key entities
- companyNRx Pharmaceuticals
Clinical-stage biopharmaceutical developing NRX-100 (IV ketamine) and positioning evidence for depression/suicidal ideation.
- companyOsmind, Inc.
Presented retrospective RWE poster comparing IV racemic ketamine vs intranasal esketamine using de-identified EHR data.
- academic institutionYale University Department of Psychiatry
Academic co-author listed on the poster.
